Rereading the Renal Cell Tumors

Bennington JL , Beckwith JB . Tumors of the Kidney, Renal Pelvis, and Ureter. Atlas of Tumor Pathology. 2nd series. Fascicle 12 p-130. Washington, DC: Armed Forces Institute of Pathology; 1975.

Thoenes W , Störkel S , Rumpelt HJ . Human chromo-phobe cell renal carcinoma. Virchows Arch B Cell Pathol. 1985; 48: 207–217.

Störkel S , Pannen B , Thoenes W , Steart PV , Wagner S , Drenckhalm D . Intercalated cells as a probable source for the development of renal oncocytoma. Virchows Arch B Cell Pathol. 1988; 56: 185–189.

Gu FL , Cai SL , Cai BJ , Wu CP . Cellular origin of renal cell carcinoma: an immunohistochemical study on monoclonal antibodies. Scand J Urol Nephrol Suppl. 1991; 138: 203–206.

Merino MJ , Eccles DM , Linehan WM . Familial renal cell carcinoma. In: Eble JN , Sauter G , Epstein JI , Sesterhenn IA , eds. Pathology and Genetics, Tumors of the Urinary System and Male Genital Organs (WHO Classification of Tumors). Lyon, France: IARC Press; 2004: 15–22.

Lam JS , Shvarts O , Leppert JT , Figlin RA , Belldegrun AS . Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. J Urol. 2005; 173: 1853–1862.

Patard J-J , Rioux-Leclercq N , Fergelot P . Understanding the importance of smart drugs in renal cell carcinoma. Eur Urol. 2006; 49: 633–643.

Hanna SC , Heathcote SA , Kim WY . m-TOR pathway in renal cell carcinoma. Expert Rev Anticancer Ther. 2008; 8: 283–292.

Eichelberg C , Junker K , Ljungberg B , Moch H . Diagnosis and prognostic molecular markers for renal cell carcinoma: a critical appraisal of the current state of research and clinical applicability. Eur Urol. 2009; 55: 851–863.

Sudarshan S , Sourbier C , Kong HS . Fumarate hydratase deficiency in renal cancer induces glycolytic addiction and hypoxia-inducible transcription factor 1alpha stabilization by glucose-dependent generation of reactive oxygen species. Mol Cell Biol. 2009; 29: 4080–4090.

Giubellino A , Linehan WM , Bottaro DP . Targeting the Met signaling pathway in renal cancer. Expert Rev Anticancer Ther. 2009; 9: 785–793.

Krüger S , Sotlar K , Kausch I , Horny HP . Expression of KIT (CD117) in renal cell carcinoma and renal oncocytoma. Oncology. 2005; 68: 269–275.

Leppert JT , Lam JS , Pantuck AJ , Figlin RA , Belldegrun AS . Carbonic anhydrase IX and the future of molecular markers in renal cell carcinoma. BJU Int. 2005; 96: 281–285.

Pantuck AJ , Seligson DB , Klatte T . Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer. 2007; 109: 2257–2267.

Petroulakis E , Mamane Y , Le Bacquer O , Shahbazian D , Sonenberg N . mTOR signaling: implications for cancer and anticancer therapy. Br J Cancer. 2006; 94: 195–199.

Velickovic M , Delahunt B , Grebe SKG . Loss of heterozy-gosity at 3p14.2 in clear cell carcinoma is an early event and is localized to the FHIT gene locus. Cancer Res. 1999; 59: 1323–1326.

Velickovic M , Delahunt B , Störkel S , Grebe SKG . VHL and FHIT locus loss of heterozygosity is common in all renal cancer morphotypes but differs in pattern and prognostic significance. Cancer Res. 2001; 61: 4815–4819.

Schraml P , Struckmann K , Hatz F . VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma. J Pathol. 2002; 196;186–193.

Morrisey C , Martinez A , Zatyka M . Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear and papillary renal cell carcinoma. Cancer Res. 2001; 61: 7277–7281.

Lott ST , Lovell M , Naylor SL , Killary AM . Physical and functional mapping of a tumor suppressor locus for renal cell carcinoma within chromosome 3p12. Cancer Res. 1998; 58: 3533–3537.

Kovacs G , Fucesi L , Emanual A , Kung HF . Cytogenetics of papillary renal cell tumors. Genes Chromosomes Cancer. 1991; 3: 249–255.

Schmidt L , Junker K , Weirich G . Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene. Cancer Res. 1998; 58: 1719–1722.

Bratslavsky G , Sudarshan S , Neckers L , Linehan WM . Pseudohypoxic pathways in renal cell carcinoma. Clin Cancer Res. 2007; 13: 4667–4671.

Speicher MR , Schoell B , du Manoir S . Specific loss of chromosomes 1, 2, 6, 10, 13, 17 and 21 in chromophobe renal cell carcinomas revealed by comparative genomic hybridization. Am J Pathol. 1994; 145: 356–364.

Kim HJ , Shen SS , Ayala AG . Virtual-karyotyping with SNP microarrays in morphologically challenging renal cell neoplasms: a practical and useful diagnostic modality. Am J Surg Pathol. 2009; 33: 1276–1286.

Argani P , Lal P , Hutchinson B , Lui MY , Reuter VE , Ladanyi M . Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions. A sensitive and specific immunohistochemical assay. Am J Surg Pathol. 2003; 27: 750–761.

Argani P , Ladanyi M . Renal carcinomas associated with Xp11.2 translocations/TFE3 gene fusions. In Eble JN , Sauter G , Epstein JI , Sesterhenn IA , eds. Pathology and Genetics, Tumors of the Urinary System and Male Genital Organs (WHO Classification of Tumors). Lyon, France: IARC Press; 2004: 37.

Kuiper RP , Schepens M , Thijssen J . Upregulation of the transcription factor TFEB in t(6;11)(p21;q13)-positive renal cell carcinomas due to promoter substitution. Hum Mol Genet. 2003; 12: 1661–1669.